Investor Relations (IR) Questions: Threshold Pharmaceuticals THLD
Click here to return to the biotech IRQ Index
Answers received: February 2013
Thank you for your inquiry. Threshold last raised cash in March 2011. We are beginning the year 2013 with approximately $100M in cash including the $30M milestone just earned for initiation of the Phase 3 MAESTRO study in pancreatic cancer; specifics will be provided with the year-end financial results to be reported next month. Last year, the net burn was approximately $35M. We do not disclose information regarding credit lines.
We are looking forward to progress on multiple fronts this year. In addition to the recent initiation of the Phase 3 study in pancreas cancer patients, we expect to complete enrollment in our Phase 3 study of TH-302 in patients with soft tissue sarcoma; completion of enrollment is expected by the end of 2013 along with an interim analysis of overall survival, which will be conducted by an independent data monitoring committee. We expect to announce the initiation of a 3rdregistrational program with TH-302 around mid-year. We also anticipate reporting preliminary results at major medical conferences this year from some of our earlier stage studies of TH-302 in multiple myeloma and leukemia, as well as in combination with antiangiogenic therapies such as sunitinib and pazopanib. Our discovery research group continues to work on the development of new drug candidates from our hypoxia activated prodrug platform for further development. We also may evaluate additional in-licensing opportunities that build on our expertise and complement our current pipeline.
Thank you for your inquiry. Threshold last raised cash in March 2011. We are beginning the year 2013 with approximately $100M in cash including the $30M milestone just earned for initiation of the Phase 3 MAESTRO study in pancreatic cancer; specifics will be provided with the year-end financial results to be reported next month. Last year, the net burn was approximately $35M. We do not disclose information regarding credit lines.
We are looking forward to progress on multiple fronts this year. In addition to the recent initiation of the Phase 3 study in pancreas cancer patients, we expect to complete enrollment in our Phase 3 study of TH-302 in patients with soft tissue sarcoma; completion of enrollment is expected by the end of 2013 along with an interim analysis of overall survival, which will be conducted by an independent data monitoring committee. We expect to announce the initiation of a 3rdregistrational program with TH-302 around mid-year. We also anticipate reporting preliminary results at major medical conferences this year from some of our earlier stage studies of TH-302 in multiple myeloma and leukemia, as well as in combination with antiangiogenic therapies such as sunitinib and pazopanib. Our discovery research group continues to work on the development of new drug candidates from our hypoxia activated prodrug platform for further development. We also may evaluate additional in-licensing opportunities that build on our expertise and complement our current pipeline.
